Loading…
Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years
Saved in:
Published in: | South African medical journal 2006-12, Vol.96 (12), p.1249 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 12 |
container_start_page | 1249 |
container_title | South African medical journal |
container_volume | 96 |
creator | Rawoot, A Little, F Heckmann, J M |
description | |
format | article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_17252153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17252153</sourcerecordid><originalsourceid>FETCH-LOGICAL-p178t-1e676d42d9b662af235841e084737d66869ab697229526310fe6e385489d24d73</originalsourceid><addsrcrecordid>eNo1j81KxDAUhbNQnHH0FeS-QKFNmqRZyuAfDAyIrodbczsTnSYhiWJ9eivq6nDg8PGdE7asuVSVkbpdsPOcX-u5S6PO2KLRXPJGiiULjy6_QRhgxKPbe_QvEzgP44S5HMg7hH3CD5chYnHkSwb6jCGThRIAv7AcXIjJeYJ5njBOMIQECCNZhx4iJRfsD1_ARJjyBTsd8Jjp8i9X7Pn25ml9X222dw_r600VG92VqiGllW25Nb1SHAcuZNc2VHetFtoq1SmDvTKacyO5Ek09kCLRybYzlrdWixW7-uXG93522c2OI6Zp9_9cfAPUHVQv</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years</title><source>DOAJ Directory of Open Access Journals</source><creator>Rawoot, A ; Little, F ; Heckmann, J M</creator><creatorcontrib>Rawoot, A ; Little, F ; Heckmann, J M</creatorcontrib><identifier>ISSN: 0256-9574</identifier><identifier>PMID: 17252153</identifier><language>eng</language><publisher>South Africa</publisher><subject>Adult ; Azathioprine - administration & dosage ; Azathioprine - adverse effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Incidence ; Male ; Medical Records ; Middle Aged ; Myasthenia Gravis - drug therapy ; Neoplasms - chemically induced ; Neoplasms - epidemiology ; Risk Factors ; South Africa - epidemiology</subject><ispartof>South African medical journal, 2006-12, Vol.96 (12), p.1249</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17252153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rawoot, A</creatorcontrib><creatorcontrib>Little, F</creatorcontrib><creatorcontrib>Heckmann, J M</creatorcontrib><title>Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years</title><title>South African medical journal</title><addtitle>S Afr Med J</addtitle><subject>Adult</subject><subject>Azathioprine - administration & dosage</subject><subject>Azathioprine - adverse effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical Records</subject><subject>Middle Aged</subject><subject>Myasthenia Gravis - drug therapy</subject><subject>Neoplasms - chemically induced</subject><subject>Neoplasms - epidemiology</subject><subject>Risk Factors</subject><subject>South Africa - epidemiology</subject><issn>0256-9574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNo1j81KxDAUhbNQnHH0FeS-QKFNmqRZyuAfDAyIrodbczsTnSYhiWJ9eivq6nDg8PGdE7asuVSVkbpdsPOcX-u5S6PO2KLRXPJGiiULjy6_QRhgxKPbe_QvEzgP44S5HMg7hH3CD5chYnHkSwb6jCGThRIAv7AcXIjJeYJ5njBOMIQECCNZhx4iJRfsD1_ARJjyBTsd8Jjp8i9X7Pn25ml9X222dw_r600VG92VqiGllW25Nb1SHAcuZNc2VHetFtoq1SmDvTKacyO5Ek09kCLRybYzlrdWixW7-uXG93522c2OI6Zp9_9cfAPUHVQv</recordid><startdate>200612</startdate><enddate>200612</enddate><creator>Rawoot, A</creator><creator>Little, F</creator><creator>Heckmann, J M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200612</creationdate><title>Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years</title><author>Rawoot, A ; Little, F ; Heckmann, J M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p178t-1e676d42d9b662af235841e084737d66869ab697229526310fe6e385489d24d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Azathioprine - administration & dosage</topic><topic>Azathioprine - adverse effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical Records</topic><topic>Middle Aged</topic><topic>Myasthenia Gravis - drug therapy</topic><topic>Neoplasms - chemically induced</topic><topic>Neoplasms - epidemiology</topic><topic>Risk Factors</topic><topic>South Africa - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rawoot, A</creatorcontrib><creatorcontrib>Little, F</creatorcontrib><creatorcontrib>Heckmann, J M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>South African medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rawoot, A</au><au>Little, F</au><au>Heckmann, J M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years</atitle><jtitle>South African medical journal</jtitle><addtitle>S Afr Med J</addtitle><date>2006-12</date><risdate>2006</risdate><volume>96</volume><issue>12</issue><spage>1249</spage><pages>1249-</pages><issn>0256-9574</issn><cop>South Africa</cop><pmid>17252153</pmid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0256-9574 |
ispartof | South African medical journal, 2006-12, Vol.96 (12), p.1249 |
issn | 0256-9574 |
language | eng |
recordid | cdi_pubmed_primary_17252153 |
source | DOAJ Directory of Open Access Journals |
subjects | Adult Azathioprine - administration & dosage Azathioprine - adverse effects Dose-Response Relationship, Drug Female Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Incidence Male Medical Records Middle Aged Myasthenia Gravis - drug therapy Neoplasms - chemically induced Neoplasms - epidemiology Risk Factors South Africa - epidemiology |
title | Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T15%3A12%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20of%20malignancy%20in%20myasthenia%20gravis%20patients%20exposed%20to%20azathioprine%20therapy%20for%20a%20median%20period%20of%203%20years&rft.jtitle=South%20African%20medical%20journal&rft.au=Rawoot,%20A&rft.date=2006-12&rft.volume=96&rft.issue=12&rft.spage=1249&rft.pages=1249-&rft.issn=0256-9574&rft_id=info:doi/&rft_dat=%3Cpubmed%3E17252153%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p178t-1e676d42d9b662af235841e084737d66869ab697229526310fe6e385489d24d73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/17252153&rfr_iscdi=true |